rethinking Thrombotic Risk in Myeloproliferative Neoplasms: Can a Common Score Improve Patient Outcomes?
For years, managing the thrombotic (blood clot) risk in patients with essential thrombocythemia (ET) and polycythemia vera (PV) has relied on established scoring systems. However, these models often overlook a crucial piece of the puzzle: your overall cardiovascular health. New research suggests a readily available tool, the QRISK3 score, could significantly refine risk stratification and ultimately improve outcomes for those living with these myeloproliferative neoplasms (MPNs).
The Limitations of Current Risk Assessments
Existing risk assessments,like the IPSET-thrombosis score,are valuable.But they don’t fully capture the impact of common conditions like hypertension,atrial fibrillation,or even high body mass index (BMI). These cardiovascular comorbidities are modifiable – meaning you can take steps too address them – and play a critical role in your individual risk profile.Researchers recognized this gap and wondered if a tool already used to predict thrombotic events in the general population could be adapted for ET and PV patients. That tool was QRISK3.
Introducing QRISK3: A Holistic Approach
The QRISK3 score is designed to comprehensively evaluate your risk by considering several clinical and demographic factors,including:
Age
History of hypertension
Atrial fibrillation
Severe mental illness
High BMI
This broader outlook led investigators to retrospectively analyze data from 490 ET patients and 447 PV patients. Their goal? To see if QRISK3 scores correlated with the occurrence of thrombotic events over time.
Study Findings: QRISK3 Demonstrates Predictive Power
After a median follow-up of 85 months for ET patients and 95 months for PV patients, the results were compelling. Patients identified as high-risk using conventional assessments also tended to have higher QRISK3 scores. Specifically:
ET: High-risk patients had a median QRISK3 score of 4.2, compared to 2.4 in low-risk patients.
PV: High-risk patients had a median QRISK3 score of 8.8, compared to 2.8 in low-risk patients.
Importantly, the study found that using a QRISK3 score above 7.5% was more effective at identifying patients at risk than traditional methods. This 7.5% cutoff is already established for assessing thrombotic risk in the general population.The Impact of Intervention: Cytoreductive Therapy
But predicting risk is only half the battle. The researchers wanted to no if acting on this facts could improve outcomes. They discovered that patients with QRISK3 scores above 7.5% who received cytoreductive therapy (medication to reduce blood cell production) experienced significantly lower rates of thrombotic events.
Here’s a breakdown of the results:
ET (QRISK3 ≥ 7.5%):
Cytoreductive therapy: 79.7% remained thrombosis-free.
Active surveillance: 64.1% remained thrombosis-free.
PV (QRISK3 ≥ 7.5%):
Cytoreductive therapy: 86.9% remained thrombosis-free.
Active surveillance: 57.1% remained thrombosis-free.
(P values were .018 for ET and .034 for PV, indicating statistical significance)
What This Means for You
These findings suggest that QRISK3 isn’t just a useful tool at diagnosis, but also for ongoing risk assessment.It provides a more complete picture of your individual risk, potentially leading to more informed treatment decisions.
As the authors concluded, QRISK3 appears to be a valid and readily available tool that can definitely help improve thrombotic risk assessment in both PV and ET. This, in turn, supports the use of active cytoreductive treatment in patients identified as high-risk.
Looking Ahead
This research opens the door to a more personalized approach to MPN management. By incorporating a broader assessment of cardiovascular risk, you and your healthcare team can work together to optimize your treatment plan and minimize your risk of potentially life-threatening thrombotic events.
*reference